[HTML][HTML] Mining actinomycetes for novel antibiotics in the omics era: are we ready to exploit this new paradigm?
O Genilloud - Antibiotics, 2018 - mdpi.com
The current spread of multi-drug resistance in a number of key pathogens and the lack of
therapeutic solutions in development to address most of the emerging infections in the clinic …
therapeutic solutions in development to address most of the emerging infections in the clinic …
Mining Actinomycetes for Novel Antibiotics in the Omics Era: Are We Ready to Exploit This New Paradigm?
O Genilloud - Antibiotics (2079-6382), 2018 - search.ebscohost.com
The current spread of multi-drug resistance in a number of key pathogens and the lack of
therapeutic solutions in development to address most of the emerging infections in the clinic …
therapeutic solutions in development to address most of the emerging infections in the clinic …
Mining actinomycetes for novel antibiotics in the omics era: are we ready to exploit this new paradigm?
O Genilloud - 2018 - cabidigitallibrary.org
The current spread of multi-drug resistance in a number of key pathogens and the lack of
therapeutic solutions in development to address most of the emerging infections in the clinic …
therapeutic solutions in development to address most of the emerging infections in the clinic …
Mining Actinomycetes for Novel Antibiotics in the Omics Era: Are We Ready to Exploit This New Paradigm?
O Genilloud - Antibiotics (Basel, Switzerland), 2018 - pubmed.ncbi.nlm.nih.gov
The current spread of multi-drug resistance in a number of key pathogens and the lack of
therapeutic solutions in development to address most of the emerging infections in the clinic …
therapeutic solutions in development to address most of the emerging infections in the clinic …
[PDF][PDF] Mining Actinomycetes for Novel Antibiotics in the Omics Era: Are We Ready to Exploit This New Paradigm?
O Genilloud - pdfs.semanticscholar.org
The current spread of multi-drug resistance in a number of key pathogens and the lack of
therapeutic solutions in development to address most of the emerging infections in the clinic …
therapeutic solutions in development to address most of the emerging infections in the clinic …
[PDF][PDF] Mining Actinomycetes for Novel Antibiotics in the Omics Era: Are We Ready to Exploit This New Paradigm?
O Genilloud - academia.edu
The current spread of multi-drug resistance in a number of key pathogens and the lack of
therapeutic solutions in development to address most of the emerging infections in the clinic …
therapeutic solutions in development to address most of the emerging infections in the clinic …
Mining Actinomycetes for Novel Antibiotics in the Omics Era: Are We Ready to Exploit This New Paradigm?
O Genilloud - Antibiotics (Basel, Switzerland), 2018 - europepmc.org
The current spread of multi-drug resistance in a number of key pathogens and the lack of
therapeutic solutions in development to address most of the emerging infections in the clinic …
therapeutic solutions in development to address most of the emerging infections in the clinic …
[HTML][HTML] Mining Actinomycetes for Novel Antibiotics in the Omics Era: Are We Ready to Exploit This New Paradigm?
O Genilloud - Antibiotics, 2018 - ncbi.nlm.nih.gov
The current spread of multi-drug resistance in a number of key pathogens and the lack of
therapeutic solutions in development to address most of the emerging infections in the clinic …
therapeutic solutions in development to address most of the emerging infections in the clinic …
Mining Actinomycetes for Novel Antibiotics in the Omics Era: Are We Ready to Exploit This New Paradigm?
O Genilloud - Antibiotics, 2018 - search.proquest.com
The current spread of multi-drug resistance in a number of key pathogens and the lack of
therapeutic solutions in development to address most of the emerging infections in the clinic …
therapeutic solutions in development to address most of the emerging infections in the clinic …